Brokerages Set Eli Lilly and Company (NYSE:LLY) Target Price at $1,169.00

Shares of Eli Lilly and Company (NYSE:LLY) have been given a consensus recommendation of “Buy” by the twenty-eight brokerages that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation, nineteen have assigned a buy recommendation and five have assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $1,174.6957.

Several research analysts recently commented on the company. Zacks Research upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. Scotiabank started coverage on Eli Lilly and Company in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 target price for the company. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently modified their holdings of the business. Sumitomo Mitsui Financial Group Inc. bought a new stake in Eli Lilly and Company during the 2nd quarter valued at about $27,000. Vermillion & White Wealth Management Group LLC increased its position in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares during the period. Evolution Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $29,000. Steph & Co. boosted its holdings in shares of Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares during the period. Finally, Financial Gravity Companies Inc. bought a new position in Eli Lilly and Company in the second quarter worth approximately $31,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Nvidia announced a major AI drug‑discovery collaboration with a reported $1 billion lab investment, reinforcing long‑term R&D acceleration and partnership value for Lilly. Nvidia And Eli Lilly To Build $1 Billion AI-Powered Drug Discovery Lab
• Positive Sentiment: Jefferies reaffirmed a Buy and set a $1,300 price target; other street notes (BMO, TipRanks coverage) continue to emphasize Lilly’s leadership in incretin/GLP‑1 franchises and multitherapy growth. This supports medium‑term upside expectations. Where is Eli Lilly and Company (LLY) Headed According to Analysts?
• Positive Sentiment: J.P. Morgan notes obesity remains front‑and‑center and reported Q4 sales beats, highlighting Lp(a) cardiovascular drugs as an additional growth lever beyond weight‑loss therapies. These messages bolster earnings durability. JPM26 Day 1: Obesity Front-and-Center, Q4 Sales Beats
• Positive Sentiment: Analysts and sell‑side notes (Zacks) point to continued strong demand for Mounjaro and Zepbound, with improving supply and global uptake offsetting pricing pressure — a near‑term revenue tailwind. How Will Mounjaro and Zepbound Sales Aid LLY’s Upcoming Q4 Results?
• Neutral Sentiment: Mixed media/opinion pieces debate valuation after a strong 2025 gain; some argue to trim exposure while many funds still list Lilly as a long‑term growth holding — suggests investor positioning remains contested. Eli Lilly: Sell It And Buy Novo Nordisk Instead
• Negative Sentiment: A compounding pharmacy sued Lilly and Novo Nordisk in Texas alleging coordinated conduct to limit access to GLP‑1s, raising legal and reputational risk that could pressure pricing/access; markets treat litigation risk as a near‑term negative. Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy
• Negative Sentiment: The FDA reportedly delayed a decision on Lilly’s oral obesity pill orforglipron (and other priority voucher awardees), a regulatory setback that catalyzed intraday selling as it defers potential market expansion vs. peers. FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report

Eli Lilly and Company Trading Down 3.8%

LLY stock opened at $1,032.51 on Friday. The firm has a fifty day moving average price of $1,049.04 and a 200 day moving average price of $868.38. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The firm has a market cap of $976.11 billion, a PE ratio of 50.51, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter last year, the business earned $1.18 earnings per share. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.